Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2006-06-13
2006-06-13
Wehbé, Anne M. (Department: 1633)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S013000, C800S014000, C435S320100, C435S455000
Reexamination Certificate
active
07060871
ABSTRACT:
The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (β-AR). β-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a β-AR transgene, a β-ARK transgene, or a β-ARK inhibitor transgene.
REFERENCES:
patent: 5789654 (1998-08-01), Lowell et al.
patent: 0351921 (1990-01-01), None
patent: 0453119 (1991-10-01), None
patent: 453119 (1991-10-01), None
Bampton (Brain Res, 841, 123-134, 1999).
Bishop (Reprod Nutr Dev, 36, 607-618, 1996).
Rulicke et al. (Experimental Physiology, 85, 6:589-601, 2000).
Sigmund (Arterioscler Thromb Vasc Biol. 20, 1425-1429, 2000).
Koch, Trends in Cardiovascular Medicine, 9, (304), pp. 77-81, 1999.
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success”, Science 270:404-410 (1995).
Marshall, “Less Hype, More Biology Needed for Gene Therapy”, Science 270:1751 (1995).
Coghlan, “Gene dream fades away”, New Scientist 148:14-15 (1995).
Günsburg et al, “Virus vector design in gene therapy”, Molecular Medicine Today pp. 410-417 (1995).
Froecking et al, “Powerful and versatile enhancer-promoter unit for mammalian expression vectors”, Gene 45:101-105 (1986).
Koch et al, “Cellular Expression of the Carboxyl Terminus of a G Protein-coupled Receptor Kinase Attenuates Gβγ-mediated Signaling”, J. Biological Chem. 269:6193-6197 (1994).
Lee et al, “Cardiac and Pulmonary Replacement”, J. Thoracic Cardiovascular Surgery 111(1):246-252 (1996).
Fuller et al, “Genetic Engineering of Cardiac Muscle Cells:In VitroandIn Vivo”, Genetic Engineering 16:17-27 (1994).
Luckow et al, “CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements”, Nucleic Acids Research 15(13):5490 (1987).
Ngo et al, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, K. Merz, Jr. and S. Le Grand, Editors, Birkhauser Bost Inc., pp. 491-495 (1994).
Dillon, “Regulating gene expression in gene therapy”, TIBTECH 11:167-173 (1993).
Rigby, “Gene therapy; a long and winding road”, Current Opinion in Genetics and Development 5:397-398 (1995).
Orkin et al, “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, pp. 1-50, Dec. 7, 1995.
Kobilka et al., “cDNA for the human β2-adrenergic receptor: A protein with multiple . . . ,” Proc. Natl. Acad. Sci. USA, vol. 84, Jan. 1987, pp. 46-50.
Kass-Eisler et al., “Quantitative determination of adenovirus-mediated gene delivery . . . ,” Proc. Natl. Acad. USA, vol. 90, Dec. 1993, pp. 11498-11502.
Stratford-Perricaudet et al., “Widespread Long-term Gene Transfer to Mouse Skeletal . . . ,” J. Clin. Invest., vol. 90, Aug. 1992, pp. 626-630.
Guzman et al., “Efficient Gene Transfer into Myocardium by Direct Injection of Adenovirus Vectors,” Circulation Research, vol. 73, 1993, pp. 1202-1207.
Bertin et al., “Specific atrial overexpression of G protein coupled human β1adrenoceptors . . . ,” Cardiovascular Research, vol. 27, 1993, pp. 1606-1612.
Metzger et al, “Skeletal troponin C reduces contractile sensitivity to acidosis in cardiac . . . ,” Proc. Natl. Acad. Sci. USA, vol. 90, Oct. 1993, pp. 9036-9040.
Ren et al., “Constitutively Active Mutants of the α2-Adrenergic Receptor,” The Journal of Biological Chemistry, vol. 268, No. 22, Aug. 5, 1993, pp. 16483-16487.
Pauletto et. al., “Propranolol-induced changes in ventricular isomyosin composition in the rat,” American Heart Journal, vol. 109, Jun. 1985, pp. 1269-1273.
Bristow et al., “Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor . . . ,” The New England Journal of Medicine, vol. 307, No. 4, Jul. 22, 1982, pp. 205-211.
Bristow et al., β-Adrenergic Function in Heart Muscle Disease and Heart Failure, J. Mol. Cell. Cardiol. 17 (Supp. 2), 1985, pp. 41-52.
Bristow et al., “β-Adrenergic Pathways in Nonfailing and Failing Human Ventricular Myocardium,” Circulation, vol. 82 (Suppl. I), 1990, pp. I-12-I-25.
Fowler et. al., “Assessment of the β-adrenergic receptor pathway in the intact failing human heart: . . . ,” Circulation, vol. 74, No. 6, Dec. 1986, pp. 1290-1302.
Ungerer et al., “Altered Expression of β1-Adrenergic Receptor Kinase and β-Adrenergic . . . ” Circulation, vol. 87, 1993, pp. 454-463.
Koch et al., “The Binding Site for the βT Subunits of Heterotrimeric G Proteins . . . ,” The Journal of Biological Chemistry, vol. 268, No. 11, Apr. 15, 1993, pp. 8256-8260.
Benovic et al., “β-Adrenergic Receptor Kinase: Primary Structure Delineates a Multigene Family,”Science, vol. 246, Oct. 13, 1989, pp. 235-240.
Hausdorff et al., “Turning off the signal: desensitization of β-adrenergic recepetor function,” The FASEB Journal, vol. 4, Aug. 1990, pp. 2881-2889.
Lohse et al., “Multiple Pathways of Rapid β2-Adrenergic Receptor Desensitization,” The Journal of Biological Chemistry, vol. 265, No. 6, Feb. 25, 1990, pp. 3202-3209.
Inglese et al., “Structure and Mechanism of the G Protein-coupled Receptor Kinases,” The Journal of Biological Chemistry, vol. 268, No. 32, Nov. 15, 1993, pp. 23735-23738.
Ng et al., “Cardiac Myosin Heavy Chain mRNA Expression and Myocardial Function in the Mouse Heart,” Circulation Research, vol. 68, No. 6, Jun. 1991, pp. 1742-1750.
Medford et al., “Molecular Mechanisms Regulating VCAM-1, ICAM-1 and E-Selectin Gene Expression in Human Aortic Smooth Muscle Cells”, Clinical Research, vol. 41, No. 2, 1993, p. 145A.
Pitcher et al., “Role of βT Subunits of G Proteins in Targeting the β-Adrenergic . . . ,”Science, vol. 257, Aug. 28, 1992, pp. 1264-1267.
Yatani et al., “A G Protein Directly Regulates Mammalian Cardiac Calcium Channels,” Science, vol. 238, Nov. 1987, pp. 1288-1292.
Koch Walter J.
Lefkowitz Robert J.
Milano Carmelo A.
Rockman Howard A.
Duke University
Nixon & Vanderhye P.C.
Wehbe Anne M.
LandOfFree
Use of exogenous β-adrenergic receptor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of exogenous β-adrenergic receptor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of exogenous β-adrenergic receptor and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615424